Articles

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

UPMC GRC11-GRECHY, AP-HP Hôpital Pitié-Salpêtrière, Paris, France
Istanbul Üniversitesi, Turkey
Institut Català d’Oncologia (ICO), Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
Hôpital Bretonneau CHU de Tours, France
Onkologische Schwerpunktpraxis Lübeck, Germany
Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Hospital de Santa Maria, Lisbon, Portugal
IQVIA, St Ouen, France
F. Hoffmann-La Roche Ltd., Basel, Switzerland
F. Hoffmann-La Roche Ltd., Basel, Switzerland
University Hospital Vall d’Hebron, Barcelona, Spain
Internal Medicine III, Ulm University, Germany
Hematology, ‘Sapienza’ University, Rome, Italy
Vol. 103 No. 11 (2018): November, 2018 https://doi.org/10.3324/haematol.2017.186387